Investigational Drug Information for Firibastat
✉ Email this page to a colleague
What is the drug development status for Firibastat?
Firibastat is an investigational drug.
There have been 5 clinical trials for Firibastat.
The most recent clinical trial was a Phase 1 trial, which was initiated on June 25th 2020.
The most common disease conditions in clinical trials are Hypertension, Myocardial Infarction, and Infarction. The leading clinical trial sponsors are Quantum Genomics SA, Quotient Sciences, and Eurofins Optimed.
There are five US patents protecting this investigational drug and ninety-one international patents.
Summary for Firibastat
| US Patents | 5 |
| International Patents | 91 |
| US Patent Applications | 16 |
| WIPO Patent Applications | 8 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2020-06-25) |
| Vendors | 34 |
Recent Clinical Trials for Firibastat
| Title | Sponsor | Phase |
|---|---|---|
| Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH) | PRA Health Sciences | Phase 3 |
| Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH) | Quantum Genomics SA | Phase 3 |
| Firibastat in Treatment-resistant Hypertension | Quantum Genomics SA | Phase 3 |
Clinical Trial Summary for Firibastat
Top disease conditions for Firibastat
Top clinical trial sponsors for Firibastat
US Patents for Firibastat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Firibastat | ⤷ Start Trial | Compounds and compositions comprising the same for treating hypertension or heart failure | Centre National de la Recherche Scientifique CNRS , Institut National de la Sante et de la Recherche Medicale INSERM , Quantum Genomics SA , College de France | ⤷ Start Trial |
| Firibastat | ⤷ Start Trial | Derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulfonates) and compositions comprising the same | Institute National de la Sante et de la Recherche Medicale (Inserm) (Paris Cedex, FR) | ⤷ Start Trial |
| Firibastat | ⤷ Start Trial | Method for the preparation of (3S, 3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) | QUANTUM GENOMICS (Paris, FR) | ⤷ Start Trial |
| Firibastat | ⤷ Start Trial | Method for the preparation of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) | QUANTUM GENOMICS (Massy, FR) | ⤷ Start Trial |
| Firibastat | ⤷ Start Trial | Crystalline phase of (3S,3S′) 4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid) with L-lysine | Quantum Genomics SA | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Firibastat
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Firibastat | Austria | AT455097 | 2023-08-06 | ⤷ Start Trial |
| Firibastat | Canada | CA2533432 | 2023-08-06 | ⤷ Start Trial |
| Firibastat | Cyprus | CY1109950 | 2023-08-06 | ⤷ Start Trial |
| Firibastat | Germany | DE602004025119 | 2023-08-06 | ⤷ Start Trial |
| Firibastat | Denmark | DK1651596 | 2023-08-06 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
